Clinical trial shows by 2030 that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms
Salute e medicinaOne-OffManifold MarketsChiusoSenza KYCDati di risoluzione verificatiDiscretamente calibratoQuesto mercato si è risolto: Yes (77.7%)
Risolto: 3 ott 2026, 01:08
Risoluzione verificata dal provider
CoinRithm dispone di prove del provider sul vincitore e sul momento di regolamento di questo mercato.
Esito Vincente
Yes
A 7 giorni
—
A 24 ore
78%
ConsensoAvviso sulla qualità dei datiDati obsoleti
Dati al 3 ott 2026, 07:01 UTC · criterio pm-quality-4
Cronologia delle Probabilità
Yes77.7%
No22.299999999999997%
Vinta
Persa
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsBy 2030, will LLMs have a bigger impact on the economy than GLP-1 receptor agents?
Manifold MarketsWill a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
Manifold MarketsWhen will the FDA reclassify BPC-157 to Category 1?
KalshiHantavirus pandemic in 2026?
PolymarketRegole
Resolution criteria
- This market will resolve to "Yes" if, by December 31, 2030, a peer-reviewed clinical trial demonstrates that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms in humans.
- The trial must be published in a reputable medical journal and show statistically significant improvements in osteoarthritis symptoms compared to a control group.
- The primary outcome measures should include validated assessments of pain, physical function, and/or structural changes in the affected joints.
- If no such study is published by the specified date, the market will resolve to "No".
- If such a study sets out to investigate this and finds no significant reduction of such symptoms before market end date the market also resolves "No".